Cargando…
Challenges for Clinical Drug Development in Pulmonary Fibrosis
Pulmonary fibrosis is a pathologic process associated with scarring of the lung interstitium. Interstitial lung diseases (ILDs) encompass a large and heterogenous group of disorders, a number of which are characterized by progressive pulmonary fibrosis that leads to respiratory failure and death. Id...
Autores principales: | White, Eric S., Thomas, Matthew, Stowasser, Susanne, Tetzlaff, Kay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841605/ https://www.ncbi.nlm.nih.gov/pubmed/35173620 http://dx.doi.org/10.3389/fphar.2022.823085 |
Ejemplares similares
-
Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme
por: Valenzuela, Claudia, et al.
Publicado: (2020) -
Research Progress in the Molecular Mechanisms, Therapeutic Targets, and Drug Development of Idiopathic Pulmonary Fibrosis
por: Ma, Hongbo, et al.
Publicado: (2022) -
Repurposing of Pirfenidone (Anti-Pulmonary Fibrosis Drug) for Treatment of Rheumatoid Arthritis
por: Gan, Donghao, et al.
Publicado: (2021) -
Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib
por: Bonella, Francesco, et al.
Publicado: (2015) -
Hyperoside Attenuates Bleomycin-Induced Pulmonary Fibrosis Development in Mice
por: Huang, Jizhen, et al.
Publicado: (2020)